AID mis-targeting is poorly understood but contributes significantly to B cell genome instability. Two new papers in Cell reveal that AID mistargeting occurs primarily in gene bodies within a nuclear microenvironment characterized by high levels of transcriptional activity, interconnected transcriptional regulatory elements, and overlapping sense and antisense (convergent) transcription.
During their development and function, B lymphocytes face a daunting series of challenges to genome integrity. Early in development, they must withstand multiple DNA double-strand breaks made by the RAG1/RAG2 endonuclease during assembly of immunoglobulin (Ig) heavyand light-chain genes. Subsequently, activated B cells must deal with a bevy of mutations and DNA strand breaks triggered by the activation-induced deaminase (AID) during the processes of somatic hypermutation (SHM) and class switch recombination (CSR). Mistakes made during these reactions, including the erroneous targeting of non-Ig genes by RAG and AID, are the cause of many of the mutations and chromosomal aberrations found in B cell malignancies (Alt et al., 2013; Nussenzweig and Nussenzweig, 2010) . Preventing mis-targeting of AID is a particular challenge because, unlike RAG, AID has no DNA-binding motif demarcating its appropriate target sites. It has proven difficult to explain why AID targets certain non-Ig genes, but not others-an issue of considerable importance because many erroneous AID targets are key B lineage regulators and potent proto-oncogenes. Two papers in this issue of Cell (Meng et al., 2014; Qian et al., 2014 ) take a major step forward in unraveling this mystery by linking AID mistargeting to the process of convergent transcription within domains of highly interconnected transcriptional regulatory elements.
AID initiates SHM and CSR by deaminating cytosine residues in singlestranded DNA to yield uracil bases. The resulting U:G mismatches are processed into mutations (for SHM) or doublestranded breaks (for CSR) via DNA repair pathways involving general base excision repair factors, mismatch repair factors, and error-prone DNA polymerases (Di Noia and Neuberger, 2007) . AID targets are invariably transcribed, and AID interacts with a number of components of the transcription machinery, including RNA polymerase II (Pol II), the Pol II stalling factor Spt5, the single-strand DNAbinding complex RPA, and the RNA exosome. Such factors, acting in the context of stalled Pol II, are thought to recruit AID and create the single-stranded DNA substrate required for its action (Keim et al., 2013) . Transcription per se, however, does not provide a ready explanation for why only certain transcribed non-Ig genes are targeted by AID or why Ig genes sustain mutations due to SHM at far higher levels than non-Ig genes (Storb, 2014) . Attention has therefore focused on a central role for Pol II stalling, with CSR target regions (switch regions) providing an example of DNA sequences that favor the accumulation and stalling of Pol II and deamination by AID (Keim et al., 2013) . It has remained a major challenge to understand the targeting preferences of AID elsewhere in the genome and to determine whether and how Pol II stalling might be involved.
Qian et al. and Meng et al. identified AID off-target DNA double-strand break (DSB) sites in the genome of activated B cells and intersected these data with an extensive array of epigenetic, nuclear architecture, and transcriptional data sets. Remarkably, most of the AID off-targets were found to lie within super-enhancers, large arrays of enhancers that accumulate high levels of activating histone marks, transcription factors, and components of the transcriptional machinery (Whyte et al., 2013) . Most of the DSB sites were found to lie within the region of overlap between a super-enhancer and the body of an active gene, but a small fraction fell in extragenic enhancers, which were themselves invariably transcribed. Qian et al. also found that the vast majority of AID-initiated lesions occurred near transcription start sites that were linked by long-distance interactions with multiple other promoters and enhancers, forming a ''regulatory cluster.'' Not all regulatory clusters or super-enhancers contained an AID off-target site, but those that did tended to be particularly large and have more ''connectivity'' (more linked promoters and enhancers) (Qian et al., 2014) . Hence, the off-target activity of AID occurs preferentially in a particular nuclear microenvironment consisting of transcriptionally active, topologically highly interconnected, super-enhancer domains.
Why were only certain genes in this permissive nuclear microenvironment targeted by AID, and why did AID attack those genes in specific locations? Using very deep global run-on sequencing (GRO-seq) data, Meng et al. provide a remarkable answer to these questions: off-target AID-mediated DNA breaks almost invariably localized to sites of overlapping sense and antisense transcription, referred to as convergent transcription. Stronger super-enhancers and higher levels of convergent transcription correlated well with higher levels of AID-mediated DSBs. Together, the data of Meng et al. Substantial mechanistic questions and puzzles remain for those hoping to understand the targeting and mis-targeting of AID. The Pol II collision model is very attractive but now needs to be rigorously tested. How the clustering of regulatory elements contributes to AID action is not known; might this relate to the finding that Ig enhancers work together to target SHM (Buerstedde et al., 2014) ? Not all sites of convergent transcription within super-enhancers are targeted by AID, suggesting that additional mechanisms might be layered on top of those uncovered by Meng et al. Metabolic pathways in cancer cells are programmed to facilitate survival and proliferation in the nonnative microenvironment of a tumor. This involves changes in both the way extracellular nutrients are captured and how they are metabolized. Historically, research efforts have focused on the wiring of glucose metabolism, owing to the seminal observations of Warburg and to the dominant role glucose plays in many basic biosynthetic processes (Vander Heiden et al., 2009 ). The importance of other fuel sources, including glutamine, lipids, and protein, have received more recent attention upon realization that pathways governing their metabolism are often driven by oncogenes. In this issue of Cell, new studies from the McKnight and Tu (Comerford et al., 2014) and Maher and Bachoo labs (Mashimo et al., 2014) illustrate that a variety of cancers are also capable of capturing and metabolizing exogenous acetate and that this represents a metabolic adaptation that some tumors use to facilitate growth.
Acetate, when ligated to coenzyme A (acetyl-CoA), is among the most central and dynamic metabolites in intermediary metabolism (Figure 1) . It can be generated by the oxidation of glucose, glutamine, or fatty acids; it is used to biosynthesize nucleotides, amino acids, and both principle components of the cell membrane in mammals (i.e., fatty acids and cholesterol); and it contributes to enzyme and gene regulation by reversibly adding to nonhistone protein and histone tails, respectively (Figure 1 ) (Kaelin and McKnight, 2013) . Indeed, numerous studies have illustrated the fundamental roles that acetyl-CoA regulation plays in cell growth and proliferative processes (Wellen and Thompson, 2012) . However, under oxygen limiting conditions, as are often seen in the microenvironment of a tumor, the ability of a cell to make acetyl-CoA is severely hampered. Intrigued by this conundrum, and based on the mechanisms by which yeast generate acetyl-CoA, Comerford et al. (2014) explored the functional relevance of the mammalian homologs of the yeast enzymes that generate acetyl-CoA. Mammals express three isoforms of short-chain acyl-CoA synthetases (ACSS) that convert acetate and coenzyme-A into acetyl-CoA by consuming ATP. Two of these are localized in mitochondria (ACSS1 and ACSS3), and one can access both the nuclear and cytoplasmic space, ACSS2 (Watkins et al., 2007) . Comerford et al. (2014) find that knockdown of ACSS2, but not the mitochondrial isoforms, dramatically impairs the incorporation of exogenously supplied acetate into lipids and histone protein. These results illustrate that proliferating mammalian cells, including cancer cells, can consume and contribute acetate carbon to the cellular pool of acetyl-CoA.
In a parallel study, Mashimo et al. (2014) similarly find that exogenous acetate is captured and metabolized, here by human cancer cells grown in the brain of mice. The authors examined acetate metabolism in this context based on an earlier observation that a significant proportion of carbon in the acetyl-CoA pool could not be accounted for by tracing glucose and glutamine metabolism (Marin-Valencia et al., 2012) . By tracing acetate carbon, Mashimo et al. (2014) reveal that TCA cycle intermediates consist of as much as 50% acetatederived carbon by mass. In contrast, non-tumor-bearing brain incorporates on the order of 10% acetate-derived carbon into TCA cycle intermediates. These
